World's first approval of new HIV drug TMC114 provides potent new treatment option with FUZEON
Basel (CH), 23 June 2006. The US approval of TMC114 (darunavir), a new boosted protease inhibitor (PI), provides the opportunity to build a potent new treatment combination with the fusion inhibitor FUZEON (enfuvirtide) that can successfully combat the HIV virus in treatment resistant patients.... ...Data have shown that up to two-thirds of patients with extensive prior exposure to anti-HIV drugs...Investigational boosted protease inhibitor, TMC114, works better with FUZEON
Exciting interim data presented at the annual ICAAC* conference show that adding FUZEON (enfuvirtide) to the investigational boosted protease inhibitor (PI), TMC114/r, more than doubles the proportion of patients reaching undetectable levels of the virus.... ...This latest study provides further evidence that FUZEON now makes undetectable viral loads more achievable for patients failing on their...